Suven Life Sciences Reports Wider Q1 Net Loss Despite Revenue Growth Aug 13, 2025
Suven Life Sciences Initiates Phase 2B Trial for Novel Depression Treatment Jul 16, 2025
Suven Life Sciences Allocates 29.85 Lakh Convertible Warrants to Abakkus Fund Jul 03, 2025
Suven Life Sciences Secures ₹857 Crore Through Preferential Issue, Backed by Market Veterans May 13, 2025
More news about Suven Life Sciences
13May 25
Suven Life Sciences Issues Convertible Warrants and Reports Q4 FY24 Financial Results
Suven Life Sciences has issued 62 lakh equity convertible warrants at Rs. 134 each to two investment funds. The company's Q4 FY24 results show a 59.70% decrease in revenue to ₹2.70 crore and an increased net loss of ₹43.90 crore. For the full FY24, revenue improved by 49.09% to ₹32.80 crore, but the company still reported a net loss of ₹105.10 crore.